Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

SAN ANTONIO, TX. – 2 December, 2024 – Frost & Sullivan researched the contract development and manufacturing organization industry and, based on its analysis, recognizes Bushu Pharmaceuticals (Pharma) with the 2024 APAC Customer Value Leadership Award. The company...
Immune-Oncology Innovations: The Future of Cancer Treatment with ICIs, CAR-T, and CAR-NK Cell Therapies

Immune-Oncology Innovations: The Future of Cancer Treatment with ICIs, CAR-T, and CAR-NK Cell Therapies

The landscape of immune-oncology (I-O) is rapidly evolving, driven by groundbreaking innovations in cell therapies and immune checkpoint inhibitors (ICIs). As the leading class of I-O agents, ICIs continue to be a foundational treatment for various cancers, while...